AiXin Life International, Inc.(AIXN.US)

Company Encyclopedia

AiXin Life International, Inc.

AIXN.US

AiXin Life International, Inc. develops, manufactures, markets, and sells healthcare, nutritional products, and wellness supplements in the People's Republic of China. The company operates through four segments: Direct Sales, Pharmacy, Hotel, and Manufacture and Sale. It offers herbs, greens, and traditional Chinese remedies; and functional products, such as weight management tools, probiotics, and foods and drinks; and rhino king, colostrum powder derived from goat’s milk, tong li ke, gammaoling granules, amoxicillin capsules, loratadine tablets, and fuyang granules.

41.54 B

AIXN.USMarket value -Rank by Market Cap -/-

Financial Score

04/01/2026 Update

DistributorsIndustry

Industry Ranking25/28

Industry medianC

Industry averageC

Score Analysis

Peer Comparison

Criteria
Rating
Profit ScoreC
- ROE64.70%A
- Profit Margin-153.07%E
- Gross Margin-34.91%E
Growth ScoreE
- Revenue YoY-52.32%E
- Net Profit YoY-21.42%D
- Total Assets YoY-40.30%E
- Net Assets YoY-93.97%E
Cash ScoreE
- Cash Flow Margin-65.33%D
- OCF YoY-52.32%E
Operating ScoreC
- Turnover0.41C
Debt ScoreE
- Gearing Ratio272.70%E

Valuation analysis

P/E

10Y

P/E

Industry Ranking

-/-

P/E
Price
High
Median
Low

P/B

10Y

P/B

Industry Ranking

-/-

P/B
Price
High
Median
Low

P/S

10Y

P/S

Industry Ranking

-/-

P/S
Price
High
Median
Low

Dividend Yield

10Y

Dividend Yield

Industry Ranking

-/-

Dividend Yield
Price
High
Median
Low

Institutional View & Shareholder

Analyst Ratings

Rating

Percentage

Price
--
Highest
--
Lowest
--

Shareholder

Ownership	%Owned	Share Chg	Report Date
Quanzhong Lin	58.14%	No Change	25/04/2025
Yao-te Wang	7.54%	No Change	25/04/2025

News

Hong Kong Stock Movement: BAO PHARMA-B's full circulation plan triggers a sharp decline in stock price, as the market reassesses liquidity and valuation risks

BAO PHARMA-B fell 10.06%; Innovent Biologics rose 2.62%, with a transaction volume of HKD 120 million; BeiGene rose 2.45%, with a transaction volume of HKD 63.77 million; CanSino Biologics fell 1.06%, with a transaction volume of HKD 50.03 million; Kelun-Biotech rose 0.71%, with a market capitalization of HKD 92.1 billion

HK Stock Movers Tracker·01/02/2026 11:12

02659

-10.12%

HK Stock Movers Tracker·01/02/2026 11:12

02659

-10.12%

Weight-Loss Drug Prices Drop in China as Patent Expiry Nears

Prices of weight-loss drugs in China, including Wegovy and Mounjaro, are dropping as patent expirations approach. Wegovy's price has halved to CNY987.48 from CNY1,893.67, while Mounjaro's presale price is now as low as CNY450, down from CNY2,180. Novo Nordisk's price cuts aim to enhance patient compliance. The patent for semaglutide (Wegovy) expires on March 20, prompting domestic firms to prepare generic versions. This price reduction is expected to impact the industry and future weight-loss drug pricing significantly.

Yicai·12/29/2025 21:05